Obviousness

Obviousness Analysis under 35 U.S.C. § 103

A patent claim may be deemed obvious under 35 U.S.C. § 103 if "the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains." This analysis is based on the framework established in Graham v. John Deere Co., which involves:
(A) Determining the scope and content of the prior art.
(B) Ascertaining the differences between the claimed invention and the prior art.
(C) Resolving the level of ordinary skill in the pertinent art.
(D) Evaluating objective evidence (secondary considerations) relevant to non-obviousness.

The Supreme Court, in KSR Int'l Co. v. Teleflex Inc., emphasized a flexible "common sense" approach, stating that the combination of familiar elements according to known methods is likely to be obvious. An obviousness rejection requires a clear articulation of the reason(s) why the claimed invention would have been obvious, with a rational underpinning to support the legal conclusion. It is not sufficient to simply state that a combination would have been "common sense" without an articulated rationale. The prior art does not need to explicitly teach every limitation of the claim, but the examiner must explain why the differences would have been obvious to a person of ordinary skill in the art.

The legal status of US12295968 is "Active," and the anticipated expiration date is March 4, 2031. The priority date is March 5, 2010. Therefore, the relevant time for assessing obviousness is before March 5, 2010.

A person having ordinary skill in the art (POSA) in this field would likely have a strong background in molecular biology, immunology, and cancer therapeutics, potentially holding a Ph.D. or equivalent experience in these areas. This includes familiarity with antibody engineering, fusion protein design, and the mechanisms of immune tolerance in cancer.

Scope and Content of Prior Art

US12295968 relates to "Compositions and methods for targeted immunomodulatory antibodies and fusion proteins." The patent describes molecules comprising a targeting moiety fused with an immunomodulatory moiety. The targeting moiety specifically binds a target molecule (e.g., on a tumor cell, tumor microenvironment, or immune cell), and the immunomodulatory moiety binds an immunosuppressive molecule or activates a signaling function (e.g., TGF-β, PD-L1/L2, RANKL, PD-1, RANK).

The patent lists "Prior art keywords" including "tumor," "seq," "cells," "antibody," and "tgf." The "Prior art date" listed is March 5, 2010.

Given the priority date of March 5, 2010, prior art would include any patents, published patent applications, or other printed publications available to the public before this date. A published patent application can be considered prior art as of its filing date, even if published after the claimed invention's priority date, provided it was filed before the claimed invention.

To adequately analyze obviousness, specific prior art references would need to be identified and their disclosures compared to the claims of US12295968. Without a detailed list of identified prior art references that were available before the priority date of March 5, 2010, it is not possible to provide a definitive obviousness analysis.

Potential Combinations and Rationales for Obviousness

Assuming, for the purpose of this analysis, that prior art references exist that disclose the individual components of the claimed fusion proteins (i.e., various targeting moieties, immunomodulatory moieties, and their respective functions), a POSA might have been motivated to combine them. The patent itself highlights existing challenges in cancer immunotherapy, such as weak immunogenicity of tumor antigens and diverse mechanisms employed by tumors to evade immunologic attack, which it aims to overcome. This explicitly states a problem that a POSA would seek to solve, which can provide a motivation to combine known elements.

For example, if the prior art disclosed:

1. An antibody targeting a tumor cell component (e.g., HER2/neu, EGFR1, CD20, VEGF) and its effectiveness in tumor targeting.
2. An extracellular ligand-binding domain of TGF-βRII and its ability to sequester TGF-β, thereby counteracting immunosuppression.
3. The general concept of creating fusion proteins by linking functional protein domains.

A POSA, recognizing the immunosuppressive role of TGF-β in the tumor microenvironment, and the need to enhance anti-tumor immunity, would likely have been motivated to combine these elements. The rationale would be to improve cancer therapy by delivering an immunosuppressive-blocking agent directly to the tumor, thereby locally counteracting immune tolerance and enhancing the efficacy of other anti-cancer treatments. The patent itself describes such a strategy as "counteracting tumor-induced immune tolerance and enhance the antitumor efficacy of chemotherapy by activating and leveraging T cell-mediated adaptive antitumor immunity against resistant or disseminated cancer cells".

Similarly, for other claimed immunomodulatory moieties (PD-1, RANK, PD-L1, TGF-β, RANKL) and targeting moieties, if their individual functions and general methods of fusion protein construction were known in the prior art, a POSA would have had a motivation to combine them to achieve targeted immunomodulation in the context of cancer. The patent explicitly states that it "provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment", and that it aims to disrupt "immunosuppressive networks in the tumor microenvironment". These statements articulate the problems being addressed and the desired outcomes, which would serve as strong motivations for a POSA to combine known elements to achieve these goals.

The various exemplary fusion proteins shown in the figures (e.g., FIGS. 2-69) and their corresponding SEQ ID NOs (e.g., SEQ ID NOs: 1-69) represent specific embodiments of the general concept of a targeting moiety fused with an immunomodulatory moiety. If the individual components of these specific sequences were known, and the general principles of protein engineering and linker technologies (such as those mentioned with SEQ ID NO: 104 and 105) were understood, then the creation of these specific fusion proteins could be considered obvious.

Conclusion on Obviousness

Without specific prior art references that explicitly disclose the individual components of the claimed invention and the problems they solve, a conclusive obviousness determination is not possible. However, given the general descriptions within the patent of existing problems in cancer immunotherapy and the stated solutions through targeted immunomodulation, a POSA would have been motivated to combine known elements to address these challenges. If the individual targeting and immunomodulatory moieties, and the techniques for creating fusion proteins, were known in the prior art, then the claimed compositions and methods could be considered obvious as predictable uses of prior art elements according to their established functions to achieve a desired therapeutic outcome.